Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant, sustained weight loss (5-20% body weight reduction) in adults with obesity or overweight with comorbidities, primarily by delaying gastric emptying and reducing central appetite signaling.
If you have obesity or overweight with related health issues, GLP-1 medications like semaglutide or tirzepatide are currently the most effective pharmacological tools available in Europe. They work by mimicking hormones that tell your brain you are full and slowing down digestion. While they require weekly injections and may cause temporary stomach issues, they can lead to significant, sustained weight loss (often 15% or more) when combined with diet and exercise changes. Older weight loss drugs are largely unavailable due to safety risks.
GLP-1 analogues cause a delay in gastric emptying, which translates into a prolonged feeling of postprandial satiety. Through a central inhibitory effect on the subjective sense of satiety, GLP-1 analogues may present a positive effect on the induction of weight loss.
Why this rating
The paper cites large, randomized, double-blind, placebo-controlled trials (STEP 5, NEJM studies) published in high-impact journals.
Source
Review of upcoming and currently available anti-obesity drugs in Europe
Patryk Gryszkiewicz et al. · Journal of Education Health and Sport · 2023
DOI 10.12775/jehs.2023.30.01.005
More from this paper
- Sibutramine, a serotonin-norepinephrine reuptake inhibitor, was withdrawn from the European market because it significantly increases the risk of serious cardiovascular events (stroke, heart attack, cardiac arrest) without providing sufficient long-term benefit.Strong
- Orlistat, a lipase inhibitor, promotes modest weight loss (approx. 2-3 kg over 24 weeks) by blocking the absorption of dietary fat, but is associated with gastrointestinal side effects and potential fat-soluble vitamin deficiencies.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →